Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition

被引：6
|
作者：
Van Poznak, Catherine [1 ]
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
来源：
BREAST CANCER RESEARCH | 2010年 / 12卷 / 03期
关键词：
ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; FOLLOW-UP; PREVENTION; OSTEOPOROSIS; RISEDRONATE; TRIAL;
D O I：
10.1186/bcr2584
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The use of adjuvant aromatase inhibitors is associated with an increased risk of osteoporosis and fractures. The oral bisphosphonate, risedronate - dosed as the US Food and Drug Administration approved for the treatment or prevention of postmenopausal osteoporosis - appears to mitigate bone loss associated with 2 years of adjuvant anastrozole in women with early-stage breast cancer.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition
    Catherine Van Poznak
    [J]. Breast Cancer Research, 12
  • [2] Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy
    Marilyn L. Kwan
    Song Yao
    Cecile A. Laurent
    Janise M. Roh
    Charles P. Quesenberry
    Lawrence H. Kushi
    Joan C. Lo
    [J]. Breast Cancer Research and Treatment, 2018, 168 : 523 - 530
  • [3] Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy
    Kwan, Marilyn L.
    Yao, Song
    Laurent, Cecile A.
    Roh, Janise M.
    Quesenberry, Charles P., Jr.
    Kushi, Lawrence H.
    Lo, Joan C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 523 - 530
  • [4] Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important
    Markopoulos, Christos
    [J]. BREAST CANCER RESEARCH, 2010, 12 (04)
  • [5] Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important
    Christos Markopoulos
    [J]. Breast Cancer Research, 12
  • [6] Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer
    Sakaguchi, Koichi
    Ono, Hisako
    Nakatsukasa, Katsuhiko
    Ishikawa, Takashi
    Hasegawa, Yoshie
    Takahashi, Masato
    Niikura, Naoki
    Koizumi, Kei
    Sakurai, Teruhisa
    Shigematsu, Hideo
    Takahashi, Shunji
    Taira, Shinichiro
    Suzuki, Masato
    Narui, Kazutaka
    Miura, Daishu
    Yamada, Kimito
    Yoshimura, Mana
    Shioya, Hisashi
    Konishi, Eiichi
    Isao, Yokota
    Imai, Kojiro
    Fujikawa, Kei
    Taguchi, Tetsuya
    [J]. MEDICINE, 2019, 98 (32)
  • [7] Exercise Effects on Bone Mineral Density in Women With Breast Cancer Receiving Adjuvant Chemotherapy
    Schwartz, Anna L.
    Winters-Stone, Kerri
    Gallucci, Betty
    [J]. ONCOLOGY NURSING FORUM, 2007, 34 (03) : 627 - 633
  • [8] EFFECT OF ADJUVANT THERAPY ON BONE MINERAL DENSITY IN CAUCASIAN WOMEN WITH BREAST CANCER
    Tsagareli, M.
    Giorgadze, E.
    Khachidze, N.
    Dolidze, N.
    Sulikashvili, T.
    Jeiranashvili, N.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S228 - S229
  • [9] Oral bisphosphonate treatment prevents the changes of bone mineral density and bone biomarkers in postmenopausal Japanese women with early breast cancer treated with aromatase inhibitor
    Chaki, O.
    Kurasawa, K.
    Ishikawa, T.
    Nomura, Y.
    Yoshikata, H.
    Kikuchi, R.
    Hirahara, F.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S409 - S409
  • [10] Impact of adjuvant aromatase inhibitors on bone mineral density in breast cancer patients
    Lai, C. N.
    Correa, P. D.
    Alhasso, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345